

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**China Animal Healthcare Ltd.**

**中國動物保健品有限公司\***

(Incorporated in Bermuda with limited liability)  
(Hong Kong Stock code: 0940)

#### **UPDATES ON RECENT DEVELOPMENT OF SUSPENSION OF TRADING**

This announcement is made by China Animal Healthcare Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated 14 November 2017 and 20 November 2017 in relation to, among other things, the suspension of trading of the shares of the Company.

Reference is made to the announcement of the Company dated 4 May 2018 in relation to the date of meeting of the board of directors of the Company (the “**Board**”) for the purpose of, among others, considering and approving the financial results of the Company.

Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as defined in the above announcements.

The review hearing was held on 19 April 2018, during which the Listing Committee of the Stock Exchange (the “**Listing Committee**”) considered the request made by the Company for review of the Listing Department’s decision set out in their letter dated 3 November 2017 (the “**Department’s Decision**”).

On 27 April 2018, the Company received a facsimile from the Stock Exchange notifying the Company that the Listing Committee decided to uphold the Department’s Decision to commence the procedures under Rule 6.10 of the Listing Rules to cancel the Company’s listing on the ground that the Company is no longer suitable for listing (the “**Listing Committee’s Decision**”).

Under Rule 2B.06(2) of the Listing Rules, the Company has the right to have the Listing Committee’s Decision referred to the Listing (Review) Committee for review. A review request shall be made within 7 business days of receipt of the relevant decision. On 7 May 2018, the Company has lodged a request to the Listing (Review) Committee for reviewing the Listing Committee’s Decision.

Notwithstanding that Listing Committee’s Decision above, the Board would like to assure its shareholders that the Company has all along been and will continue making its best endeavours and taking active and prompt steps to fulfil the resumption conditions imposed by the Stock Exchange and address other concerns of the Stock Exchange, including but not limited to the publication of (i) the annual results of the Company and its subsidiaries for the year ended 31 December 2014; (ii) the interim results of the Company and its subsidiaries for the six months ended 30 June 2015; (iii) the annual results of the Company and its subsidiaries for the year ended 31 December 2015, (iv) the interim results of the Company and its subsidiaries for the six months ended 30 June 2016; and (v) the annual results of the Company and its subsidiaries for the year ended 31 December 2016 (as announced in the announcement of the Company dated 4 May 2018).

The Company will keep its shareholders and the public informed on any significant development of trading in the Company’s shares and will make further disclosure when required pursuant to the requirement of the Listing Rules.

## **CONTINUAL SUSPENSION OF TRADING**

At the request of the Company, the shares of the Company have been suspended from trading on the Stock Exchange from 9 a.m. on 30 March 2015. Trading in the Company's shares will continue to suspend until further notice.

**Shareholders and potential investors are advised to exercise caution when dealing in the Shares.**

By order of the Board  
**China Animal Healthcare Ltd.**  
**Song Yanmei**  
*Chairman, Executive Director*

Hong Kong, 7 May 2018

*As at the date of announcement, the executive Directors are Ms. Song Yanmei and Mr. Wang Yongwei; and the independent non-executive Directors are Mr. Cai Huiyi, Mr. Liu Zhanmin and Mr. Zhang Suqiang.*

*\* For identification purpose only*